Tony Arulanandam

Tony Arulanandam

Company: Tolereg Therapeutics

Job title: Founder


Founder, Tolereg Therapeutics. We are developing antigen specific Treg cell therapies for rare monogenic and polygenic autoimmune/inflammatory diseases. We have developed preclinical animal disease proof of concept in autoimmune and allergy models using TCR, CAR and BAR (B cell antigen receptor)- Treg cell therapy modalities. The BAR-Treg cell therapy allows targeting of Tregs to autoantibody producing pathogenic memory B cells in rare autoimmune diseases and food and environmental antigen mediated diseases. Preclinical development studies in select clinical indications are currently ongoing.


Panel Discussion: Exploring the Various Treg Directed Approaches 4:30 pm

Highlighting the impoartance of furthering the understanding of Treg cell biology including exploring the relevant mechanisms of action Addressing how to improve and expand Treg cell manufacturing and engineering How can clincal outcomes regulatory T cell therapies be improved?Read more

day: Day One

Antigen Specific Treg Cell Therapy Using TCRs, CARs & BAR’s to Treat Autoinflammatory & Allergic Diseases 3:00 pm

Preclinical proof of concept in Autoinflammatory and Allergic Disease models Research scale Treg cell therapy manufacturing Treg cell therapy candidate selection and translational studies to select clinical indications and IND enabling toxicology and GMP manufacturingRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.